Exhibit 10.25

SECOND AMENDMENT TO

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT

THIS SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the "Second Amendment") is entered into as of February 28, 2006 (the "Second Amendment Effective Date") by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation ("ACADIA") with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES LLC a Delaware limited liability company, ("Allergan"), with offices at 2525 Dupont Drive, Irvine, CA 92623, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

RECITALS

WHEREAS, the parties previously entered into that certain Collaborative Research, Development and License Agreement, dated September 24, 1997 (as amended by the First Amendment described below, the "1997 Agreement"), pursuant to which the parties conducted collaborative research regarding, among other things, receptor selective compounds with the goal of establishing drug discovery programs related to such receptor selective compounds;

WHEREAS, the 1997 Agreement was first amended on March 27, 2003 (the "First Amendment") to continue the collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered into a new Collaborative Research, Development and License Agreement (the "2003 Agreement") regarding ACADIA's chemical-genomics assets;

WHEREAS, the Research Terms of both of the 1997 Agreement and the 2003 Agreement (collectively, the "Agreements") will expire on March 27, 2006; and

WHEREAS, the parties wish to continue their research collaboration under the Agreements on alpha adrenergic receptors and this Second Amendment provides for further research on alpha adrenergic receptors pursuant to the terms of the Agreements as amended by the terms set forth below (the "Alpha Adrenergic Research Program"); and

WHEREAS, the parties may wish to continue to collaborate on other receptor selective compounds included in ACADIA's chemical-genomics assets on the terms set forth below.

NOW THEREFORE, in consideration of the foregoing and the covenants and premises contained in this Second Amendment, the parties hereby agree as follows:

详见附件